Q-omics provides the consensus-scored IGLVI-56 profile across patient tissues and cancer cell-line models. IGLVI-56 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IGLVI-56 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, IGLVI-56 RNA expression shows 6,093 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, KIRP, and STAD as cancer lineages where IGLVI-56 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLVI-56 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLVI-56 survival associations across molecular data types. IGLVI-56 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLVI-56 RNA expression–survival associations across cancer types. High IGLVI-56 expression shows unfavorable associations in LIHC, THCA and KIRP, but favorable associations in SKCM, COAD and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for IGLVI-56 RNA expression.
This table summarizes IGLVI-56 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for IGLVI-56. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLVI-56 shows lower tumor expression in KIRP, COAD, READ and KIRC and higher tumor expression in KICH and LUAD. The KIRP box plot shows higher IGLVI-56 RNA expression in normal versus tumor tissue (log2 FC = −0.190, t-test p < 0.001).
This table shows molecular features associated with IGLVI-56 in patient tissues and cancer cell lines. In patient samples, IGLVI-56 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
